Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors
This medicine is currently in Phase III clinical development for treatment of human epidermal growth factor receptor 2 positive (HER2+) breast and specific gastric cancer tumors. The agreement